consisting of gE, gI, gB, gD, gH, gL, gC, gG, gK, gM, and the extracellular domain of gE.

26. The cell or cell population of claim **21**, wherein the viral antigen is a VZV antigen selected from the group consisting of gE and gI.

27. The cell or cell population of claim **21**, wherein the viral antigen is an adenovirus antigen selected from the group consisting of hexon protein and penton protein.

28. The cell or cell population of claim **21**, wherein the viral antigen is a CMV antigen selected from the group consisting of pp65, immediate early (IE) antigen, and IE1.

29. The cell or cell population of claim **21**, wherein the viral antigen is an EBV antigen selected from the group consisting of latent membrane protein 2 (LMP2), Epstein-Barr nuclear antigen 1 (EBNA1), and BZLF1.

30. The cell or cell population of any one of claims **1-29**, wherein the inhibitor of a cell-mediated immune response is an immune checkpoint inhibitor.

31. The cell or cell population of claim **30**, wherein the immune checkpoint inhibitor is selected from the group consisting of programmed death 1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), B- and T-lymphocyte attenuator (BTLA), T cell immunoglobulin mucin-3 (TIM-3), lymphocyte-activation protein 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), natural killer cell receptor 2B4 (2B4), and CD160.

32. The cell or cell population of claim **31**, wherein the immune checkpoint inhibitor is PD-1.

33. The cell or cell population of any one of claims **1-29**, wherein the inhibitor of a cell-mediated immune response is transforming growth factor β (TGF-β) receptor.

34. The cell or cell population of any one of claims **1-33**, wherein the cell further recombinantly expresses a suicide gene.

35. The cell or cell population of claim **34**, wherein the suicide gene comprises inducible Caspase 9.

36. A regulatory T cell that recognizes and is sensitized to a viral antigen, which regulatory T cell recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.

37. A population of regulatory T cells, which cell population comprises T cells that recognize and are sensitized to a viral antigen and which recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.

38. The cell or cell population of claim **36** or **37**, wherein the regulatory T cell is isolated from a subject having a chronic viral infection.

39. A regulatory T cell isolated from a subject having a viral infection, which regulatory T cell recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.

40. A population of regulatory T cells isolated from a subject having a viral infection, which cell population comprises regulatory T cells which recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.

41. The cell or cell population of claim **39** or **40**, which is derived from a human.

42. The cell or cell population of claim **41**, wherein the viral infection is infection with a virus that is a human pathogen.

43. The cell or cell population of any one of claims **39-42**, wherein the viral infection is a chronic viral infection.

44. The cell or cell population of any one of claims **39-43**, wherein the viral infection is infection with HCV, HBV, HIV, HSV, VZV, adenovirus, CMV or EBV.

45. An immunoinhibitory cell, which cell is isolated from a subject having a viral infection, which immunoinhibitory cell recombinantly expresses a dominant negative form of an inhibitor of an immunoinhibitory cell-mediated immune response.

46. A population of immunoinhibitory cells isolated from a subject having a viral infection, which cell population comprises immunoinhibitory cells which recombinantly express a dominant negative form of an inhibitor of an immunoinhibitory cell-mediated immune response.

47. The cell or cell population of claim **45** or **46**, which is derived from a human.

48. The cell or cell population of claim **47**, wherein the viral infection is infection with a virus that is a human pathogen.

49. The cell or cell population of any one of claims **45-48**, wherein the viral infection is a chronic viral infection.

50. The cell or cell population of claim **45** or **46**, wherein the immunoinhibitory cell is a regulatory T cell.

51. The cell or cell population of any one of claims **45-49**, wherein the immunoinhibitory cell recognizes and is sensitized to a viral antigen of the virus of the viral infection.

52. The cell or cell population of any one of claims **45-50**, wherein the immunoinhibitory cell recombinantly expresses a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen of the virus of the viral infection.

53. The cell or cell population of any one of claims **36-44** or **50-52**, wherein the regulatory T cell is a human $CD4^+$ $CD25^+$ T cell.

54. The cell or cell population of any one of claims **36-44** or **50-52**, wherein the regulatory T cell is a human $CD4^+$ $CD127^{lo/-}CD25^+$ T cell.

55. A polyclonal population of human regulatory T cells that are $CD4^+CD25^+$, are sensitized to a viral antigen, and recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.

56. The polyclonal population of cells of claim **55**, wherein the human regulatory T cells are $CD127^{lo/-}$.

57. The cell or cell population of any one of claims **36-38**, which is derived from a human.

58. The cell or cell population of claim **57**, wherein the viral antigen is of a virus that is a human pathogen.

59. The cell or cell population of any one of claims **36-38** or **51-58**, wherein the viral antigen can elicit an immune response in a human subject infected with the virus.

60. The cell or cell population of any one of claims **36-38** or **51-59**, wherein the viral antigen is selected from the group consisting of a hepatitis C virus (HCV) antigen, a human immunodeficiency virus (HIV) antigen, a hepatitis B virus (HBV) antigen, a herpes simplex virus (HSV) antigen, a varicella zoster virus (VZV) antigen, an adenovirus antigen, a cytomegalovirus (CMV) antigen, and an Epstein-Barr virus (EBV) antigen.

61. The cell or cell population of claim **60**, wherein the viral antigen is a HCV antigen selected from the group consisting of core protein, envelope protein E1, envelope protein E2, NS2, NS3, NS4, and NS5.

62. The cell or cell population of claim **60**, wherein the viral antigen is a HIV antigen selected from the group